216869-36-2

Basic information

• Product Name: 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-, (5S)-
• Synonyms: (5S)-5-(aminomethyl)-3-[3-fluoro-4-(1,4-thiazinan-4-yl)phenyl]-1,3-oxazolidin-2-one;(5S)-5-(aminomethyl)-3-[3-fluoro4-(1,4-thiazinan4-yl)phenyl]-1,3-oxazolidin-2-one;(S)-5-Aminomethyl-3-(3-fluoro-4-thiomorpholin-4-yl-phenyl)-oxazolidin-2-one;(S)-N-[3-(3-fluoro-4-thiomorpholinylphenyl)-2-oxo-5-oxazolidinyl]methylamine
• CAS NO: 216869-36-2
• Molecular Formula: C14H18FN3O2S
• Molecular Weight: 311.38
• Mol File: 216869-36-2.mol

Chemical Properties

• Boiling Point: 505.9±50.0 °C(Predicted)
• Density: 1.340±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-, (5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-, (5S)-(216869-36-2)
• EPA Substance Registry System: 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-, (5S)-(216869-36-2)

Safety Data

• Hazardous Substances Data: 216869-36-2(Hazardous Substances Data)

Upstream product

• 168828-73-7 Toluene-4-sulfonic acid (R)-3-(3-fluoro-4-thiomorpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl ester 
• 168828-74-8 (R)-<3-<3-fluoro-4-(4-thiomorpholinyl)phenyl>-2-oxo-5-oxazolidinyl>methyl azide 
• 168828-71-5 [3-fluoro-4-(4-thiomorpholinyl)phenyl]carbamic acid, phenylmethyl ester 
• 168828-72-6 (R)-<3-<3-fluoro-4-(4-thiomorpholinyl)phenyl>-2-oxo-5-oxazolidinyl>methanol 
• 168828-70-4 (4-(2-fluoro-4-nitrophenyl)thiomorpholine) 
• 237432-11-0 (3-fluoro-4-thiomorpholin-4-ylphenyl)amine 
• 369-34-6 3,4-difluoronitrobenzene 

Downstream Products

• 221201-58-7 (R)-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]isothiocyanate 
• 168828-60-2 N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 
• 1280555-32-9 C₂₂H₂₄FN₅O₄S₂ 
• 1280555-33-0 C₂₃H₂₆FN₅O₄S₂ 
• 1280555-34-1 C₂₇H₂₆FN₅O₄S₂ 
• 1430414-19-9 C₂₀H₂₁ClFN₃O₄S₂ 
• 1430414-28-0 C₂₀H₂₁F₂N₃O₄S₂ 
• 1430414-27-9 C₁₈H₂₀FN₃O₄S₃ 
• 1430414-26-8 C₂₁H₂₁F₄N₃O₄S₂ 
• 1430414-24-6 C₂₃H₂₃FN₄O₄S₂ 
• 1430414-22-4 C₂₆H₂₆FN₃O₅S₂ 
• 1430414-21-3 C₂₀H₂₀ClF₂N₃O₄S₂ 

Relevant articles and documents

RETRACTED ARTICLE: Design, synthesis of novel oxazolidino-amides/sulfonamides conjugates and their impact on antibacterial activity

Abstract: In view of generating new compounds for future drug development, we have synthesized oxazolidinones library of aryl amides and aryl sulfonamide derivatives. These compounds were screened in vitro against panel of susceptible and resistant Gram-p

Synthesis, biological evaluation of new oxazolidino-sulfonamides as potential antimicrobial agents

A number of linezolid-like oxazolidino-sulfonamides (7a-y and 8a-b) were designed and synthesized with a view to develop antimicrobial agents with improved properties. Most of the synthesized compounds showed good to moderate activity against a panel of standard Gram-positive and Gram-negative bacteria and fungal strains. The compounds 7i and 7v exhibited significant activity, with a MIC value of 2.0-6.0 μg/mL against a panel of Gram-positive and Gram-negative bacteria. These compounds also showed activity against Candida albicans, with a MIC value of 4.0 μg/mL. A correlation of the antimicrobial activity with calculated lipophilicity values (C log P) is also presented.

OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPERATION AND THEIR USE AS ANTIMYCOBACTERIAL AGENTS

Novel compounds belonging to the class of oxazolidinones possessing potent antimycobacterial properties especially useful in the treatment of acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai. The compound and its pharmaceutically acceptable salts thereof act as antibacterial agents. Also disclosed is a method for inhibiting growth of mycobacterial cells a well as a method of treating mycobacterial conditions such as Mycobacterium tuberculoses, drug resistant Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai, comprising administering an antimycobacterially effective amount of the said compound and/or pharmaceutically acceptable salts thereof. There is also disclosed a process for the manufacture of the said compound or its pharmaceutically acceptable salts.

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.

During the course of our investigations in the oxazolidinone antibacterial agent area, we have identified a subclass with especially potent in vitro activity against mycobacteria. The salient structural feature of these oxazolidinone analogues, 6 (U-10048